Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies

Oncogene. 2018 Mar;37(12):1561-1575. doi: 10.1038/s41388-017-0045-7. Epub 2018 Jan 11.

Abstract

Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Brain Neoplasms / genetics
  • Brain Neoplasms / therapy*
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / physiology*
  • Glioblastoma / genetics
  • Glioblastoma / therapy*
  • Humans
  • Molecular Targeted Therapy* / methods
  • Molecular Targeted Therapy* / trends
  • Protein Kinase Inhibitors / therapeutic use*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics

Substances

  • Protein Kinase Inhibitors
  • epidermal growth factor receptor VIII
  • EGFR protein, human
  • ErbB Receptors